Diaceutics’ Pharma Precision Medicine Readiness Report 2019: It's time to rethink the testing—treatment relationship - Diaceutics

Diaceutics’ Pharma Precision Medicine Readiness Report 2019: It’s time to rethink the testing—treatment relationship

The diagnostic testing ecosystem is broken, hindering the progress of Precision Medicine in 2019, according to Diaceutics’ just published Pharma Precision Medicine Readiness Report 2019. In this latest annual assessment of the state of Precision Medicine, Diaceutics calls on the Precision Medicine community to rethink the relationship between testing and treatment, and end the “siloed thinking that is denying patients access to the right tests and better treatments.”

In the Report, Diaceutics draws on its experience with more than 500 therapy/diagnostic projects and the insights derived from real-world data to depict the toll that this fragmented commercial approach is having on patients. The Report reveals the challenges and strategic mistakes that continue to impair the onward march of Precision Medicine, including those involving the diagnostic supply chain, relations between the Pharma and Lab industries, suboptimal investment in biomarker/therapy combinations, and core hurdles to optimal precision testing facing Pharma commercial teams.

Additionally, the Report

  • Describes Diaceutics’ solution to this broken diagnostic testing ecosystem through the global harmonization of clinical lab tests,
  • Identifies the megatrends characterizing Precision Medicine in 2019, and
  • Predicts the drivers and disruptors that will shape Precision Medicine in the next 3 to 5 years.

Download the full Diaceutics Pharma Precision Medicine Readiness Report 2019  here to get the full story on Precision Medicine!

Webinars & Podcasts

PharmaVOICE 100 Celebration Marathon
Our Chief Precision Officer, Suzanne Munksted, was delighted to join the PharmaVoice100 panel discussion on Leading Global Teams earlier this month. Catch up on the vibrant discussion around how global organizations and leaders overcome the day...
Diaceutics CEO Peter Keeling's interview on RTE Radio 1 about latest £4m funding round and Precision Medicine
Interview:Diaceutics CEO Peter Keeling interviewed on RTE Radio 1 about latest £4m funding round from Silicon Valley Bank & Precision Medicine
View all

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications